Related Experiment Video
Updated: Jan 7, 2026

Capturing Common Fragile Site Breaks by Native γH2A.X ChIP
Published on: January 24, 2025
Low YTHDC1 Expression Upregulates FSCN1 to Promote Nuclear F-Actin Formation and Facilitate Double-strand DNA Breaks
Minglong Yang1,2,3,4, Wanxiang Niu1,2,3,4, Yuanfei Wang1,2,3,4
1Department of Neurosurgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
Abstract:
Glioblastoma (GBM) is an aggressive and recurrent malignancy with a poor prognosis. Although temozolomide (TMZ) is a cornerstone of GBM treatment, its efficacy is often compromised by inherent or acquired resistance, underscoring the urgent need to uncover molecular mechanisms, discover new therapeutic targets, and develop innovative treatment strategies. In this study, we found an increased formation of filamentous actin (F-actin) within the nuclei of TMZ-resistant GBM cells. We also showed that overexpression of FSCN1 in TMZ-resistant GBM cells promotes F-actin formation and facilitates the repair of DNA double-strand breaks (DSBs). Further investigation revealed a marked decrease in the expression of YTHDC1 in TMZ-resistant GBM cells, which regulates FSCN1 through m6A modification. Additionally, FSCN1 activates the CDC42/N-WASP/Arp2/3 signaling pathway by recruiting FGD1 to activate CDC42GTP, which drives nuclear F-actin formation. Importantly, combining the FSCN1 inhibitor NP-G2-044, with TMZ therapy resulted in stronger anti-tumor effects both in vitro and in vivo. In conclusion, the study demonstrates that nuclear F-actin formation in GBM promotes DSB repair and reveals that targeting FSCN1 with NP-G2-044 could be a promising strategy for enhancing treatment outcomes and improving the prognosis for GBM patients.
Insights
Glioblastoma cells resistant to temozolomide show increased nuclear filamentous actin (F-actin). Targeting FSCN1 with NP-G2-044 enhances anti-tumor effects, offering a new strategy for glioblastoma treatment.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Glioblastoma (GBM) is an aggressive brain tumor with poor prognosis.
- Temozolomide (TMZ) resistance limits GBM treatment efficacy, necessitating novel therapeutic targets.
- Understanding resistance mechanisms is crucial for improving patient outcomes.
Purpose of the Study:
- To investigate the role of nuclear filamentous actin (F-actin) in TMZ-resistant GBM.
- To identify molecular mechanisms driving F-actin formation and its impact on DNA repair.
- To evaluate the therapeutic potential of targeting FSCN1 in GBM.
Main Methods:
- Analysis of F-actin formation in TMZ-resistant GBM cells.
- Investigating the role of FSCN1, YTHDC1, and the CDC42/N-WASP/Arp2/3 pathway.
- Utilizing FSCN1 inhibitor NP-G2-044 in combination with TMZ.
- In vitro and in vivo anti-tumor efficacy studies.
Main Results:
- TMZ-resistant GBM cells exhibit increased nuclear F-actin.
- FSCN1 overexpression promotes F-actin formation and DNA double-strand break (DSB) repair.
- YTHDC1 downregulation correlates with TMZ resistance and regulates FSCN1 via m6A modification.
- FSCN1 activates the CDC42/N-WASP/Arp2/3 pathway, driving nuclear F-actin.
- Combined NP-G2-044 and TMZ therapy showed enhanced anti-tumor effects.
Conclusions:
- Nuclear F-actin formation in GBM promotes DSB repair, contributing to TMZ resistance.
- Targeting FSCN1 with NP-G2-044 is a promising strategy to overcome TMZ resistance.
- This approach could improve treatment outcomes and prognosis for GBM patients.
More Related Videos
12:19Tools to Study the Role of Architectural Protein HMGB1 in the Processing of Helix Distorting, Site-specific DNA Interstrand Crosslinks
Published on: November 10, 2016
10:47Immunofluorescence Microscopy of γH2AX and 53BP1 for Analyzing the Formation and Repair of DNA Double-strand Breaks
Published on: November 3, 2017
Related Concept Videos
Abnormal Proliferation
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle